statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting...

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Announces $6 Million Registered Direct Offering BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, April 1, 2024 TEL AVIV, Israel, April 1, 2024...

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Stock analysts at HC Wainwright lowered their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst...

HC Wainwright Brokers Reduce Earnings Estimates for BioLineRx Ltd. (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings estimates for BioLineRx in a report released on Tuesday, March 26th. HC Wainwright...

HC Wainwright Weighs in on BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX)

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX  Free Report) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price...

HC Wainwright Reaffirms Buy Rating for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX  Get Free Report) was upgraded by equities research analysts at StockNews.com to a sell rating in a report issued on Wednesday.
Separately, HC Wainwright...

StockNews.com Upgrades BioLineRx (NASDAQ:BLRX) to Sell

BioLineRx Ltd. (NASDAQ:BLRX  Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 324,700...

BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx (NASDAQ:BLRX  Get Free Report)s stock had its buy rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently...

HC Wainwright Reiterates Buy Rating for BioLineRx (NASDAQ:BLRX)

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel...

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 PR Newswire TEL AVIV, Israel, March 20, 2024 - Management to...

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Volume	759,134.00
52-Wk High	$2.53
52-Wk Low	$0.5908

BLRX BioLineRx, Ltd.

About

Feed

News

Fundamentals